NeurogesX Announces Preliminary Results From Second Phase 3 Clinical Trial In HIV DSP
Mar 3rd 2008Drug InformationPain / Anesthetics
NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced preliminary top-line results from study C119, its second Phase 3 clinical trial of NGX-4010, the Company’s dermal patch drug candidate, in patients with HIV-distal sensory polyneuropathy (HIV-DSP).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
